Abstract
Despite a safe, effective vaccine, hepatitis B virus (HBV) vaccination coverage remains low among people who inject drugs (PWID). Characteristics of participants screened for a trial investigating the efficacy of financial incentives in increasing vaccination completion among PWID were examined to inform targeting of vaccination programs. Recruitment occurred at two health services in inner-city Sydney that target PWID. HBV status was confirmed via serological testing, and questionnaires elicited demographic, drug use, and HBV risk data. Multinomial logistic regression was utilized to determine variables independently associated with HBV status. Of 172 participants, 64% were susceptible, 17% exposed (HBV core antibody-positive), and 19% demonstrated evidence of prior vaccination (HBV surface antibody ≥ 10 mIU/ml). Compared with exposed participants, susceptible participants were significantly more likely to be aged less than 35 years and significantly less likely to be receiving current opioid substitution therapy (OST) and to test hepatitis C antibody-positive. In comparison to vaccinated participants, susceptible participants were significantly more likely to be male and significantly less likely to report daily or more frequent injecting, current OST, and prior awareness of HBV vaccine. HBV vaccination uptake could potentially be increased by targeting younger, less frequent injectors, particularly young men. In addition to expanding vaccination through OST, targeting “at risk” youth who are likely to have missed adolescent catch-up programs may be an important strategy to increase coverage. The lack of an association between incarceration and vaccination also suggests increasing vaccination uptake and completion in adult and juvenile correctional facilities may also be important.
Similar content being viewed by others
References
National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2010. Sydney: National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales; 2010.
Australian Government Department of Health and Ageing. Australian immunisation handbook. 9th ed. Canberra; 2008.
Lugoboni F, Quaglio G, Civitelli P, Mezzelani P. Bloodborne viral hepatitis infections among drug users: the role of vaccination. Int J Environ Res Public Health. 2009; 6(1): 400–413.
Gidding HF, Warlow M, MacIntyre CR, et al. The impact of a new universal infant and school-based adolescent hepatitis B vaccination program in Australia. Vaccine. 2007; 25(51): 8637–8641.
Tawk HM, Vickery K, Bisset L, Selby W, Cossart YE. The impact of hepatitis B vaccination in a Western country: recall of vaccination and serological status in Australian adults. Vaccine. 2006; 24(8): 1095–1106.
Fattovich G. Natural history of hepatitis B. J Hepatol. 2003; 39(Suppl 1): S50–S58.
Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet. 2006; 368(9539): 938–945.
National Centre in HIV Epidemiology and Clinical Research. Australian NSP Survey National Data Report 2005–2009. Sydney: National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales; 2010.
Maher L, Chant K, Jalaludin B, Sargent P. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia. J Gastroenterol Hepatol. 2004; 19(10): 1114–1120.
Day CA, White B, Dore GJ, et al. Hepatitis B virus among injecting drug users in Sydney, Australia: prevalence, vaccination and knowledge of status. Drug Alcohol Depend. 2010; 108(1–2): 134–137.
Miller ER, Hellard ME, Bowden S, Bharadwaj M, Aitken CK. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. J Infect. 2009; 58(5): 375–382.
Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990–1995. Med J Aust. 1997; 167(1): 17–20.
Ramasamy P, Lintzeris N, Sutton Y, Taylor H, Day CA, Haber PS. The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. Addiction. 2010; 105(2): 329–334.
Macdonald V, Dore GJ, Amin J, van Beek I. Predictors of completion of a hepatitis B vaccination schedule in attendees at a primary health care centre. Sex Health. 2007; 4(1): 27–30.
Topp L, Day C, Dore GJ, Maher L. Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: a review. Drug Alcohol Rev. 2009; 28(6): 669–675.
Amesty S, Ompad DC, Galea S, et al. Prevalence and correlates of previous hepatitis B vaccination and infection among young drug-users in New York City. J Community Health. 2008; 33(3): 139–148.
de la Fuente L, Toro C, Brugal MT, et al. Poor validity of self-reported HBV vaccination among young heroin users in Spain supports the policy “don’t ask, draw a blood sample, vaccinate and try to schedule another visit”. J Clin Virol. 2007; 38(1): 87–90.
Lo Re V III, Frank I, Gross R, et al. Self-reported hepatitis B and C virus infections had low sensitivity among HIV-infected patients. J Clin Epidemiol. 2007; 60(3): 294–299.
Kuo I, Mudrick Daniel W, Strathdee Steffanie A, Thomas David L, Sherman Susan G. Poor validity of self-reported hepatitis B virus infection and vaccination status among young drug users. Clin Infect Dis. 2004; 38(4): 587–590.
Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J. Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. Br Med J. 1999; 319: 290–291.
Schlicting EG, Johnson ME, Brems C, Wells RS, Fisher DG, Reynolds G. Validity of injecting drug users’ self report of hepatitis A, B, and C. Clin Lab Sci. 2003; 16(2): 99–106.
Rhodes T, Hunter GM, Stimson GV, et al. Prevalence of markers for hepatitis B virus and HIV-1 among drug injectors in London: injecting careers, positivity and risk behaviour. Addiction. 1996; 91(10): 1457–1467.
Maher L, Barnes K, Topp L, Day C, (on behalf of the Hepatitis Acceptability and Vaccine Incentives Trail—HAVIT Group). Use of incentives to increase vaccination uptake and completion in injecting drug users. 11th National Immunisation Conference; September 2008; Gold Coast.
Deacon R, Day C, Topp L, et al. Using financial incentives to increase hepatitis B immunisation completion in people who inject drugs: a randomised controlled trial. Australasian Professional Society on Alcohol and other Drugs Conference; Darwin: Drug Alcohol Rev; 2009:A13.
Deacon RM, Topp L, Wand H, et al. Correlates of hepatitis B vaccination status among injecting drug users: a comparison of eligible and ineligible participants in the HAVIT trial. 7th Australasian Viral Hepatitis Conference; September 2010; Melbourne.
Metzger DS, Koblin B, Turner C, et al. Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. Am J Epidemiol. 2000; 152(2): 99–106.
Des Jarlais DC, Paone D, Milliken J, et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet. 1999; 353(9165): 1657–1661.
Gossop M, Darke S, Griffiths P, et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995; 90(5): 607–614.
Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on early detection of persons with harmful alcohol consumption–II. Addiction. 1993; 88(6): 791–804.
MacDonald MA, Wodak AD, Dolan KA, van Beek I, Cunningham PH, Kaldor JM. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995–1997. Med J Aust. 2000; 172(2): 57–61.
Kaye S, Darke S. Determining a diagnostic cut-off on the Severity of Dependence Scale (SDS) for cocaine dependence. Addiction. 2002; 97(6): 727–731.
Ross J, Teesson M, Darke S, et al. The characteristics of heroin users entering treatment: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Rev. 2005; 24(5): 411–418.
Winstock AR, Anderson CM, Sheridan J. National survey of HIV and hepatitis testing and vaccination services provided by drug and alcohol agencies in Australia. Med J Aust. 2006; 184(11): 560–562.
van Beek I. Case study: accessible primary health care—a foundation to improve health outcomes for people who inject drugs. Int J Drug Policy. 2007; 18(4): 329–332.
Day CA, Islam M, White A, Reid SE, Hayes S, Haber PS. Development of a nurse-led primary healthcare service for injecting drug users in inner-city Sydney. Aust J Prim Health. 2011; 17(1): 10–15.
Huang L, Gilbert M-L, Rossi M, et al. Trends in vaccine-induced immunity to hepatitis B among Canadian street-involved youth. J Urban Health. 2010; 87(2): 337–348.
Lum PJ, Hahn JA, Shafer KP, et al. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. J Viral Hepat. 2008; 15(3): 229–236.
Smith JA, Braunack-Mayer A, Wittert G. What do we know about men’s help-seeking and health service use? Med J Aust. 2006; 184(2): 81–83.
Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour: literature review. J Adv Nurs. 2005; 49(6): 616–623.
Green CA, Pope CR. Gender, psychosocial factors and the use of medical services: a longitudinal analysis. Soc Sci Med. 1999; 48(10): 1363–1372.
Kuo I, Sherman SG, Thomas DL, Strathdee SA. Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Drug Alcohol Depend. 2004; 73: 69–78.
Seal KH, Edlin BR, Ochoa KC, Tulsky JP, Moss AR, Hahn JA. Risk of hepatitis B infection among young injection drug users in San Francisco: opportunities for intervention. West J Med. 2000; 172(1): 16–20.
Justice Health. Justice health Area Health Service Plan 2010 and Beyond. Sydney: NSW Department of Health; 2009.
Acknowledgments
We thank participants and staff from the Kirketon Road Centre and the Redfern Primary Health Clinic, including Ann White, John Kearley, and Charlene Murdock, and HAVIT research assistant M. Mofizul Islam. HAVIT is funded by NHMRC Project Grant number 510104. Carolyn Day is supported by a National Health and Medical Research Council (NHMRC) Public Health Post Doctoral Fellowship. Paul Haber is supported by an NHMRC Practitioner Fellowship and Lisa Maher by a NHMRC Senior Research Fellowship. The Kirby Institute (formerly the National Centre in HIV Epidemiology and Clinical Research) is funded by the Australian Government Department of Health and Ageing and is affiliated with the Faculty of Medicine, The University of New South Wales. The views expressed in this publication do not necessarily represent the position of the Australian Government.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deacon, R.M., Topp, L., Wand, H. et al. Correlates of Susceptibility to Hepatitis B among People Who Inject Drugs in Sydney, Australia. J Urban Health 89, 769–778 (2012). https://doi.org/10.1007/s11524-012-9680-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11524-012-9680-z